Please ensure Javascript is enabled for purposes of website accessibility

Why Arrowhead Pharmaceuticals Shares Dropped 15% in February

By Taylor Carmichael - Mar 9, 2020 at 8:37AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

After a stellar 2019, the biotech stock has lost 47% so far in 2020.

What happened

Arrowhead Pharmaceuticals (ARWR 2.04%), a market darling in 2019, lost 15% of its valuation in February, according to data provided by S&P Global Market Intelligence. This is part of a larger free fall in the biotech's stock price in 2020. Arrowhead's valuation has dropped almost 50% since Jan. 2. 

While some of this fall is due to fears from COVID-19, the stock started dropping way before that was an issue. So what's going on?

businessmen falling off a cliff

Image source: Getty Images.

So what

Arrowhead Pharmaceuticals is a biotech company that is focused on RNA interference (RNAi) drugs. What shot the company to prominence was its deal with Johnson & Johnson in 2018. The pharmaceutical giant paid $250 million to license Arrowhead's hepatitis B drug. That deal provided a lot of necessary cash to the young biotech, and it was a validation of Arrowhead's science. The stock more than tripled in 2018, running up 237%.      

The news was even better in 2019. The company reported positive data from all its clinical trials. That sent the stock soaring 410% last year. For those scoring at home, the stock tripled in 2018 and then quintupled in 2019.     

So part of the problem is that Arrowhead is a victim of its own success. All the good news from the last two years sent the stock into the stratosphere. When the company's valuation hit $6.3 billion in early 2020, some observers figured the stock would take a hit, just because of its valuation. And so far, that's exactly what has happened.

To make five times your money in a year is a wonderful return, and Arrowhead used that opportunity to turn its share price into some cash. Its secondary offering was priced at $58 a share, raising approximately $232 million for the company in December. 

The cash raise was just a reminder that Arrowhead has no drugs on the market. Like other unprofitable biotechs, it needs cash to stay alive while all its drugs make their way through clinical trials. So while the stock started off the year at $63 a share, it soon fell below the secondary price, and then kept falling. A negative note and underperform rating from analyst Mani Foroohar at SVB Leerink didn't help the stock, either. Add in the COVID-19 panic, and that's how you get an almost 50% haircut in a little over two months.  

Now what

The good news for long-term investors is that the investment thesis is still intact. Clinical trial data continues to impress. None of the company's drugs are in phase 3 trials yet, so Arrowhead is at least a couple of years away from having any drugs on the market. Still, while general market panic over COVID-19 might send the whole market down in the short term, the long-term picture for Arrowhead remains bright. Investors should keep their eyes on the clinical data and not get scared off by market gyrations.

  

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Arrowhead Pharmaceuticals, Inc. Stock Quote
Arrowhead Pharmaceuticals, Inc.
ARWR
$35.93 (2.04%) $0.72
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$177.43 (-0.05%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
311%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.